The spironolactone derivative drospirenone is combined with ethinylestradiol or estetrol in
combined oral contraceptives. Formulations with 17-β-estradiol are used to treat climacteric …

Progesterone has a high affinity for the mineralocorticoid receptor and is an antagonist of
aldosterone. Almost all synthetic progestogens are devoid of an antimineralocorticoid effect …

The use of combined estrogen/progesterone has been shown to result in an increased
cardiovascular risk in randomised double-blinded trials. However, these studies used oral …

Purpose: Steroid hormones in hormonal contraceptives influence a variety of metabolic
parameters. Mainly, ethinyloestradiol (EE) in combined hormonal contraceptives (CHC) is a …

The pharmacology and pharmacokinetics of drospirenone, a unique progestogen, are
reviewed in this paper. Unlike other progestogens, drospirenone, an analogue of …

Drospirenone is a novel synthetic progestogen with a pharmacological profile similar to that
of natural progesterone. It has been developed in combination with ethinylestradiol for use …

Considerable advances have been made in the field of combined oral contraceptives since
their introduction 50 years ago. This ongoing evolution has been focused on reducing the …

Drospirenone is a novel progestogen that possesses antimineralocorticoid activity. This
activity is seen clinically in its effects on physiological parameters, body weight, general well …

Drospirenone 3mg with ethinylestradiol 20µg (Yaz®) is a low-dose combined oral
contraceptive (COC) administered in a regimen of 24 days of active tablets followed by a …

Unlike other currently available progestogens, drospirenone (DRSP) has a pharmacological
profile, which closely mimics that of endogenous progesterone, most notably potent anti …